Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03546426
Title Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)
Acronym MESOVAX
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.